GoHealth (GOCO) Q2 2024 earnings summary

Executive summary

• Q2 2024 net revenues declined 25.9% year-over-year to $105.9 million, driven by a 6.4% decrease in Submissions and a shift from non-agency to agency revenue.

• Net loss for Q2 2024 ranged from $26.0 million to $59.3 million, showing improvement from prior year periods.

• Adjusted EBITDA was negative $12.3 million, down from positive $0.8 million in Q2 2023, reflecting lower revenues and operational challenges.

• Internal captive agent submissions rose 14% year-over-year, offsetting a 33% decline from external GPS agents.

• Strategic shift from enrollment to engagement, with investments in technology, AI, and proprietary workflows to enhance consumer experience and operational efficiency.

Financial highlights

• Q2 2024 net revenues were $105.9 million, down from $143 million in Q2 2023; six months ended June 30, 2024 revenues were $291.5 million, down 10.6% year-over-year.

• Adjusted EBITDA for Q2 2024 was negative $12.3 million, a $13 million decrease year-over-year.

• Year-to-date cash flow from operations was negative $24 million, compared to $31 million generated in the prior year.

• Trailing twelve months cash flow from operations was $53.8 million, down from $85.9 million a year ago.

• Sales per Submission decreased 19% year-over-year to $690 for Q2 2024.

Outlook and guidance

• Management anticipates growth in Submission volume, revenue, and Adjusted EBITDA in the second half of 2024, with more clarity expected after AEP.

• Market dynamics are expected to shift in Q4 2024 with AEP, potentially driving increased shopping and switching.

• Company plans to extend or replace its Term Loan and Revolving Credit Facilities before 2025 maturities.

• Current liquidity, including cash and credit facilities, is expected to be sufficient for at least the next twelve months.

• Anticipate year-over-year decline in cash flow from operations due to a shift from non-agency revenue.